MedPage Today on MSN

First complement inhibitor wins full approval in IgA nephropathy

Iptacopan significantly slowed kidney decline in a phase III trial ...

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...
Labroots

Complement Function Expands

Complement molecules are the immune proteins responsible for identifying bacteria, viruses, and other foreign invaders as they circulate through our bodies. Their function helps lymphocytes to locate ...
clinicaladvisor.com

Nipocalimab May Reduce NMJ Damage Without Suppressing Complement Function

Nipocalimab might lower the concentration of anti-acetylcholine receptor antibodies in people with generalized myasthenia gravis, a study shows. PHOENIX, Arizona—Nipocalimab might lower the ...